CN1336235A - Health-care products for regulating immunological function and delaying senility - Google Patents
Health-care products for regulating immunological function and delaying senility Download PDFInfo
- Publication number
- CN1336235A CN1336235A CN01131281A CN01131281A CN1336235A CN 1336235 A CN1336235 A CN 1336235A CN 01131281 A CN01131281 A CN 01131281A CN 01131281 A CN01131281 A CN 01131281A CN 1336235 A CN1336235 A CN 1336235A
- Authority
- CN
- China
- Prior art keywords
- health
- cordyceps
- health product
- ganoderma
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a heath protection product capable of regulating immune function and delaying senility. It is characterized in that said product is produced from 1-4 parts ganoderma, 0.5-2.5 parts cordyceps and 0.5-3 parts lumbricus evtract to form an oral health protection product. Said product possesses stronger antioxidation ability. It can enhance antidisease function of human body, also is suitable for tumour patient to use during radio therapy and chemicotherapy to prevent recurrence and transfer after operation.
Description
(1) technical field
The present invention relates to the health product of a kind of regulating immunological function and slow down aging, specifically it is that Chinese herbal medicine with integration of edible and medicinal herbs is the pure natural Orally taken health article that raw material is made.
(2) background technology
Current, because the various diseases that immunity shortcoming and immune disorder produce grows with each passing day, especially the dead enemy of cancer serious threat human health always, be the maximum harm that the whole world more than 50 hundred million populations face jointly, according to incompletely statistics, be 1/4 of human natural death number because of the dead number of cancer stricken now, be that the whole world has more than 600 ten thousand people to die from cancer every year approximately, wherein China just accounts for more than 150 ten thousand, and cancer also presents the trend that continues rising at the sickness rate of China in recent years, and the age of onset rejuvenation, up to the present mankind treatment for cancer is performed the operation except using, radiotherapy, outside the method for chemotherapy, the special breakthrough do not occur, though there is nearly various schools of thinkers in tumour medicine enterprise, medicine has seven big classes, more than 100 kind, wherein antibiosis have kind more than ten, and plant have the 7-8 kind, kind surplus the solvation class has ten, anti-metabolism has nearly ten kinds, kind surplus enzyme and hormones and other class have ten, undesirable to most curative effect of medication, and toxic side effect.
In order to reduce and to prevent the various diseases generation of (comprising cancer), can regulate body's immunological function by health food, reach the raising Abwehrkraft des Koepers, strengthen the people's health level, reduce the generation of disease.
(3) summary of the invention
Task of the present invention just provides the health product of a kind of regulating immunological function and slow down aging, thereby improve people's resistance against diseases, reduce the generation of disease, strengthen people's health level, be being used of tumor patient postoperative and putting process also, prevent postoperative recurrence and transfer.
In order to realize above-mentioned task, adopt following technical proposal:
The health product of a kind of regulating immunological function and slow down aging is characterized in that it is to pulverize the Orally taken health article that is mixed and made into by the following weight proportion raw material under-15 ℃ of temperature:
Ganoderma 1-4 part Cordyceps 0.5-2.5 part Pheretima extract 0.5-3 part.
Described Ganoderma and Cordyceps are the powders that is crushed under-15 ℃ of temperature below 800 orders; Described Pheretima extract prepares by following method, with the clean 1.5-4.5 normal saline doubly that adds of Pheretima, under 25-50 ℃ of temperature, carry out self-dissolving earlier, remove slag through centrifugal, collect supernatant and carry out the ultrafiltration first time, M is 7-10 ten thousand posts, and the ultrafiltrate of collection carries out second ultrafiltration again, and M is 1.5-2.5 ten thousand posts, receive trapped fluid and carry out chromatography with G-75 post, adopt normal saline flushing, collect active peak, be Pheretima extract through lyophilization; Described health product are capsule preparations.
Health product of the present invention adopt Cordyceps powder, Ganoderma powder and Pheretima extract, make Orally taken health article through behind the abundant mixing, and its compound basis is:
Health product raw material of the present invention is the rare Chinese medicine of integration of edible and medicinal herbs, and sums up through a large amount of experimentatioies, wherein:
Ganoderma:
Compendium of Material Medica carries " the beneficial motive, invigorating middle warmer, increase wisdom, do not forget ", " food for a long time ", it is old to make light of one's life by commiting suicide, the angle prolongs life " etc.; Ganoderma is the sporophore of many Cordycepps of basidiomycetes Ganoderma plant, often adopts tissue isolation to separate and cultivate Ganoderma sporophore from fresh Ganoderma.
The chemical constituent of Ganoderma is very complicated, from Ganoderma, be separated to 150 so far surplus kind of chemical compound, many Ganodenic acid, ganoderans of experimental results show that, Ganoderma adenosine and organic germanium are the effective constituent that mainly contains of Ganoderma, also have four kinds of albumen polysaccharide that intensive anti-tumor activity is arranged.Ganoderma has pain relieving, calmness, inhibition histamine and discharges, detoxifies, protects the liver, kills functions such as tumor cell.The Ganoderma adenosine derivative has the effect of stronger blood viscosity lowering.Suppress platelet aggregation in the body, improve blood oxygen ability and accelerate blood circulation etc.
Experiment shows: Ganoderma can be improved the activity of superoxide dismutase (SOD), has antithrombotic to form and the raising erythrocyte deformability, can promote lymphopoiesis, improves macrophage, NK cell, the phagocytic activity of T cell and lethality.
Cordyceps:
Compendium of Material Medica carries that " lung kidney two warps are put down, gone into to sweet in the mouth, invigorating the lung and the kidney, mends that marrow, relieving cough and resolving phlegm are controlled phthisical cough, to control diaphragm disease all good." the artificial Cordyceps mycelium that isolating Cordyceps fungus becomes through fermentation culture from the Cordyceps fresh specimens.Experimental analysis shows: the composition of cultivating Cordyceps is suitable with the natural cordyceps composition.The clinical foundation that provides of the two is provided the effect basically identical.
The composition of Cordyceps mainly contains seed amino acid and 17 kinds of inorganic elementss surplus Cordyceps polysaccharide, cordycepic acid, the cordycepin and 20.
Experimental results demonstrate: natural cordyceps and artificial culture mycelium preparation thereof can quicken spleen nucleic acid and protein renewal speed, promote DN synthetic, help quickening division, the propagation of splenocyte, thereby enhancing immunity, give mice 4-8/kg, can obviously promote the propagation of mouse bone marrow cells grain-monosystem CFU-GM, strengthen hemopoietic function of bone marrow.
By engulfing experiment in the mice body, external cross match composite test and acid phosphatase enzyme activity determination etc., observed Cordyceps and artificial hyphostoma and extracted the activation of preparation, proved that the activation to peritoneal macrophage may be a kind of nonspecific immunity promoter Turnover of Mouse Peritoneal Macrophages.
Immunoregulation effect by observing Cordyceps polysaccharides and to the benefiting action of body proves that tentatively it is the active ingredient of Cordyceps nourishing and nourishing yin effect.Cordyceps polysaccharide has tangible activation to reticuloendothelial system and phagocytosis of macrophages, and lymphocyte transformation is had certain facilitation.
Cordyceps and Cordyceps mycelium 3g/kg can improve the content of murine liver tissue superoxide dismutase (SOD).Isolated experiment also has similar results, and can suppress the formation of lipid peroxide.The Cordyceps mycelium physical ability suppresses the activity of monoamine oxidase, MAO in rat and the mouse brain, in conjunction with effect prompting Cordyceps and Cordyceps mycelium to immunologic function anti-aging effects is arranged.
Pheretima:
Mainly contain hypoxanthine, fatty acid, succinic acid, cholesterol, amino acids, nucleic acid derivative, LONGSU, fibrinolytic enzyme, Pheretima detoxifcation phlogiston and a large amount of trace element etc.
Pass through autolysis, the small-molecule substance that extraction separation obtains, the result shows through zoopery, it can significantly increase mouse thymus and spleen nucleated cell number, improve the phagocytic function of Turnover of Mouse Peritoneal Macrophages, and make that the leukocyte number increases in the peripheral blood, disclose the effect that this composition has human body immunity improving power.
As mouse inoculation S
180And H
22And S
294, tumor cell such as EMT-6, through the abdominal cavity or stomach pour into Pheretima extract, show good tumor-inhibiting action.Heavy and the contrast ratio of the flat tumor of administration group, difference highly significant (P＜0.01).
Experiment is proof also, and Pheretima extract has plasminogen and directly dissolving fibrin effect in the good activation blood, reduces blood viscosity.
Behind three mutual compatibilities of component, have complementary advantages, may form the thing that induces of a kind of similar biological response modifier (BRM), mainly transfer BRM process in the body by enhancing body's immunological function, improve the NK cytoactive, strengthen phagocytic function, leukocyte increasing, reach the symptom of improving tumor patient, improve the patient to put, the tolerance of chemotherapy.Because this product has stronger antioxidative ability, so this product has the function that improves the body resist the disease.
Health product of the present invention are as being tried the test that thing is regulated immunologic function and delaying senility function, and its result is as follows:
Test basis " the function assessment assessment process and the detection method of health food ",
1, regulate immunologic function:
Select the female secondary mice in Kunming for use, body weight 18-22g divides four groups at random by body weight,
Being subjected to the examination amount is the approved product of human body recommended amounts 1.8g/ day 60kg body weight, divides basic, normal, high three dosage, is subjected to the examination group to adopt the administration by gavage administration, and once a day, matched group is irritated distilled water, continuous measurement result all around.
The result:
(1) to the influence of normal mouse body weight: see Table 1
Table 1: to the influence of normal mouse body weight (* ± SD) the back body weight P value of body weight P value experiment before the experiment of group dosage number of animals
(g/kgbw) (only) (g) dosage 0.30 12 22.1 ± 1.5 0.7634 34.7 ± 3.7 0.1700 high dose 0.60 12 21.8 ± 1.0 0.7946 33.5 ± 2.7 0.4654 in (g) matched group 0 12 21.9 ± 1.4/32.7 ± 3.1/low dosage 0.15 12 21.7 ± 2.2 0.8021 33.9 ± 2.1 0.2803
As seen from the above table, per os give being tried before the thing of mice various dose and 4 week back and matched group ratios, each dosage body group does not all have significant difference (P＞0.05).
(2) to the influence of normal mouse delayed allergy: see Table 2
Table 2: to the influence of normal mouse delayed allergy (DTH) (* ± SD)
| Group | Dosage (g/kgbw) | Number of animals (only) | Toes swelling variation different (mm) | The P value |
| Matched group | ?????0 | ????12 | ??0.53±0.15 | ??????/ |
| Low dosage | ????0.15 | ????12 | ??0.69±0.15* | ????0.0024 |
| Middle dosage | ????0.30 | ????12 | ??0.83±0.24** | ????0.0034 |
| High dose | ????0.60 | ????12 | ??0.77±0.14** | ????0.0015 |
* with matched group significant difference (P＜0.05) is arranged relatively,
* and matched group relatively have significant differences (P＜0.01),
As seen from the above table, what per os gave the mice various dose is tried thing after 4 weeks, improve 30% (P＜0.05) respectively with the toes swelling degree of the basic, normal, high dosage group of matched group, 52% (P＜0.01) and 45% (P＜0.01) (3) are to the influence of normal mice serum hemolysin: see Table 3
Table 3: to the influence of normal mice serum hemolysin (* ± SD)
| Group | Dosage (g/kgbw) | Number of animals (only) | ???????HC50 | The P value |
| Matched group | ?????0 | ????12 | ????132.1±2.5 | ?????/ |
| Low dosage | ????0.15 | ????12 | ????132.7±2.3 | ???0.5825 |
| Middle dosage | ????0.30 | ????12 | ????134.3±2.2* | ???0.0340 |
| High dose | ????0.60 | ????12 | ????134.9±3.1* | ???0.0271 |
* with matched group significant difference (P＜0.05) is arranged relatively.
As seen from the above table, that gives oral mice various dose is tried thing after 4 weeks, compares with matched group, and the HC50 of middle and high dosage group brings up to 1.7% and 2.1% (P＜0.05) respectively.
As seen, what oral administration gave the mice various dose is tried thing after 4 weeks, with the matched group ratio, the toes swelling of low dose group (0.15g/kgbw) improves 30% (P＜0.05), all other indexs there are no significant difference (P＞0.05), middle dosage group (0.3g/kgbw) toes swelling degree improves 57% (P＜0.01), and half hemolysis value improves 1.7% (P＜0.05).The toes swelling degree of high dose group (0.6g/kgbw) improves 45% (P＜0.01) half hemolysis value and improves 2.1% (P＜0.05).
2, delaying senility function:
Animal subject and dosage are the same, and each is organized mice and gives medicine continuously and measure every index after 58 days.
Result of the test:
(1) to the influence of mice serum lipid peroxide content:
(a) serum lipid peroxide assay such as following table are carried out
Table 4: serum lipid peroxide assay table
| Reagent | Markization pipe ml | The blank pipe of markization ml | Measure pipe ml | Measure blank pipe ml |
| Standard substance | ????0.1 | ????/ | ???/ | ?????/ |
| Dehydrated alcohol | ????/ | ????0.1 | ???/ | ?????/ |
| Serum | ????/ | ????/ | ???0.1 | ?????/ |
| 1.2.3 number | ????/ | ????/ | ???/ | ?????/ |
| Mix reagent | ????4 | ????4 | ???4 | ?????4 |
Behind the mixing, 95 ℃ water-soluble (uncap and boil) 40 minutes takes out back 3500-2000
rCentrifugal 10 minutes of/min, distilled water zeroing 532mm colorimetric.
(b) to the result that influences of mice serum fat content, see Table 5
Table 5: mice serum fat content influenced result (X ± SD)
| Grouping | Tried agent amount (g/kg.bw) | Number of animals (only) | The serum peroxide content | The P value |
| Matched group | ?????0 | ????10 | ????51.8±7.0 | ?????/ |
| Low dosage | ????0.15 | ????10 | ????45.5±9.5 | ????0.1052 |
| Middle dosage | ????0.30 | ????10 | ????45.1±7.3* | ????0.0499 |
| High dose | ????0.60 | ????10 | ????48.0±4.0 | ????0.1497 |
* comparing with matched group, there were significant differences.
Last table shows, what oral administration gave the aged mouse various dose was tried thing after 58 days, compared with the blank group, and middle dosage group serum lipid peroxide content reduces by 13% (P＜0.05).
(2) to the mensuration of glutathione peroxidase activity in the mice whole blood, according to the form below advances
OK, see Table 6
(a) to the mensuration of glutathione peroxidase activity in the mice whole blood
Table 6: to the mensuration table of glutathione peroxidase activity in the mice whole blood
| Reagent | Sample cell (ml) | Non-enzyme pipe (ml) | Blank pipe (ml) |
| GSH | ????0.4 | ????0.4 | ?????/ |
| Diluting blood sample liquid | ????0.4 | ?????/ | ?????/ |
| Distilled water ml | ?????/ | ????0.4 | ?????/ |
Washed 5 minutes for 37 ℃
| ??H 2O 2(ml) 37 ℃ are given temperature | ????0.2 | ????0.2 | ????/ |
| Metaphosphoric acid sinks solution | ????4.0 | ????4.0 | ????/ |
The centrifugal min of 3000r/min
| Centrifuged supernatant (ml) | ????2.0 | ????2.0 | |
| Distilled water (ml) | ????/ | ????/ | ????0.4 |
| Metaphosphoric acid precipitated liquid Na 2HPO 4(ml) | ????/ ????2.5 | ????/ ????2.5 | ????1.6 ????2.5 |
| The DTNB liquid (ml) that develops the color | ????0.5 | ????0.5 | ????0.5 |
Chromogenic reaction 1 minute is read the 0.D value in the 420nm wavelength, and measurement result sees Table 7.
(b) to the result that influences of aged mouse whole blood trough Guang peroxidase activity
Table 7: aged mouse whole blood trough Guang peroxidase activity influenced result (X ± SD)
| Group | Tried agent amount (g/kg.bw) | Number of animals (only) | GSH-PX (activity units) | The P value |
| Matched group | ??????0 | ??10 | ??21.5±1.8 | ????/ |
| Low dosage | ?????0.15 | ??10 | ??21.0±2.3 | ??0.5732 |
| Middle dosage | ?????0.30 | ??10 | ??23.3±3.2 | ??0.1367 |
| High dose | ?????0.60 | ??10 | ??23.8±2.3* | ??0.0239 |
* comparing with matched group, there were significant differences (P＜0.05)
As seen, what per os gave the aged mouse various dose was tried thing 58 days, compare with the blank group, low dose group (0.15g/ day/kg.bw), every index does not all have significant difference (P＞0.05), middle dosage group serum lipid peroxide content improves and reduces by 13% (P＜0.001), to whole blood glutathion peroxidase activity units; And high dose group improves 11% (P＜0.05) to whole blood glutathione peroxidase activity units.
3, to S
180Press down the tumor experiment: see Table 8
Table 8: to S
180Press down the tumor experimental result (* ± SD)
| Group | Dosage (g/kg.bw) | Number of animals (only) | Tumor heavy (g) | Suppression ratio (%) | The P value |
| Matched group | ?????/ | ????10 | ??4.46±2.54 | ?????0 | |
| The administration group | ??1.05/kg.bw | ????10 | ??2.35±1.91* | ????43.78 | ??0.025 |
Result of the test is tried thing to S
180Tumour inhibiting rate be 48.59% (P＜0.05).
In sum, oral administration gives the health product of the present invention of aged mouse various dose, and compare with matched group after 4 weeks: the toes swelling degree of basic, normal, high dosage group improves 30% (P＜0.05) respectively, 52% (P＜0.01) and 45% (P＜0.01).Middle and high, dosage group has significant difference to mice serum half hemolysis value and matched group ratio, improves 1.7% and 2.1% (P＜0.05) respectively.Oral administration gives the health product of the present invention of aged mouse various dose, 58 days with blank group ratio: middle dosage group (
0.30g/
Kg.bw), serum lipid peroxide content improves 13% (P＜0.001).High dose group (
0.60g/
Kg.bw), whole blood glutathione peroxidase activity units improves 11% (P＜0.05), to S
180Sarcoma has inhibitory action, and its tumour inhibiting rate is 48.59% (P＜0.05), and body weight did not have significant difference (P＞0.05) before and after each organized dosage experiments.
Judge according to " the function assessment assessment process and the detection method of health food ": health product of the present invention have the immunologic function of adjusting and delaying senility function, simultaneously to inoculation sarcoma S
180The inhibition effect is arranged.
Owing to take such scheme, make the technology of the present invention have following advantage and effect:
A) product of the present invention it adopted medicine food homologous raw materials, be the health product of a kind of immunity-regulating and slow down aging, be applicable to the edible for patients of immune dysfunction, also be suitable for being used in tumor patient postoperative and the chemicotherapy process, prevent postoperative recurrence and transfer.
B) scientific formulation is reasonable, behind the mutual compatibility of three components, have complementary advantages, can form the thing that induces of a kind of similar biological response modifier (BRM), transfer BRM process in the body, improve the NK cytoactive by the enhancing human body immunity function, strengthen cytophagous phagocytic function, leukocyte increasing reaches the symptom of improving tumor patient, improve the patient to put, the tolerance of chemotherapy, simultaneously to inoculation sarcoma S
180The inhibition effect is arranged.
(4) specific embodiment
Embodiment 1:
At first earthworm is cleaned, add 1.5 times of physiological saline and under 50 ℃ of temperature, carry out self-dissolving, remove slag through centrifugal, the supernatant of collection carries out the ultrafiltration first time, M is 70,000 posts, collect ultrafiltrate and carry out second ultrafiltration again, M is 2.5 ten thousand posts, receives trapped fluid and carries out chromatography with G-75 post, adopt normal saline flushing, collect Peak Activity, it is for subsequent use to make Pheretima extract through lyophilization, again with glossy ganoderma and Cordyceps sinensis respectively under-15 ℃ of temperature, be crushed to 800 orders, it is for subsequent use to make powder, gets at last the Pheretima extract 0.5kg of above-mentioned preparation, glossy ganoderma 4kg and Cordyceps sinensis 1.5kg, mixing granulation incapsulates under-15 ℃ of temperature, is health products of the present invention.
Embodiment 2:
At first earthworm is cleaned, add 3.0 times of physiological saline and under 40 ℃ of temperature, carry out self-dissolving, remove slag through centrifugal, the supernatant of collection carries out the ultrafiltration first time, M is 80,000 posts, collect ultrafiltrate and carry out second ultrafiltration again, M is 2.0 ten thousand posts, receives trapped fluid and carries out chromatography with G-75 post, adopt normal saline flushing, collect Peak Activity, it is for subsequent use to make Pheretima extract through lyophilization, again with glossy ganoderma and Cordyceps sinensis respectively under-15 ℃ of temperature, be crushed to 1000 orders, it is for subsequent use to make powder, gets at last the Pheretima extract 1.5kg of above-mentioned preparation, glossy ganoderma 2.5kg and Cordyceps sinensis 1.8kg, mixing granulation incapsulates under-15 ℃ of temperature, is health products of the present invention.
Embodiment 3:
At first earthworm is cleaned, add 4.5 times of physiological saline and under 25 ℃ of temperature, carry out self-dissolving, remove slag through centrifugal, the supernatant of collection carries out the ultrafiltration first time, M is 100,000 posts, collect ultrafiltrate and carry out second ultrafiltration again, M is 1.5 ten thousand posts, receives trapped fluid and carries out chromatography with G-75 post, adopt normal saline flushing, collect Peak Activity, it is for subsequent use to make Pheretima extract through lyophilization, again with glossy ganoderma and Cordyceps sinensis respectively under-15 ℃ of temperature, be crushed to 1250 orders, it is for subsequent use to make powder, gets at last the Pheretima extract 3.0kg of above-mentioned preparation, glossy ganoderma 1.0kg and Cordyceps sinensis 0.5kg, mixing granulation incapsulates under-15 ℃ of temperature, is health products of the present invention.
Claims (4)
1, the health product of a kind of regulating immunological function and slow down aging is characterized in that it is to pulverize the Orally taken health article that is mixed and made into by the following weight proportion raw material under-15 ℃ of temperature:
Ganoderma 1-4 part Cordyceps 0.5-2.5 part Pheretima extract 0.5-3 part.
2, health product according to claim 1 is characterized in that described Ganoderma and Cordyceps are the powders that is crushed to below 800 orders under-15 ℃ of temperature.
3, health product according to claim 1, it is characterized in that described Pheretima extract prepares by following method, earlier Pheretima is cleaned and added 1.5-4.5 normal saline doubly, under 25-50 ℃ of temperature, carry out self-dissolving, remove slag through centrifugal, collect supernatant and carry out the ultrafiltration first time, M is 7-10 ten thousand posts, the ultrafiltrate of collecting carries out second ultrafiltration again, M is 1.5-2.5 ten thousand posts, receives trapped fluid and carries out chromatography with G-75 post, adopts normal saline flushing, collect active peak, be Pheretima extract through lyophilization.
4, health product according to claim 1 is characterized in that described health product are capsule preparations.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN01131281A CN1121237C (en) | 2001-09-05 | 2001-09-05 | Health-care products for regulating immunological function and delaying senility |
| PCT/CN2002/000616 WO2003026683A1 (en) | 2001-09-05 | 2002-09-04 | Health caring product for enhancing immunity and delaying aging |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN01131281A CN1121237C (en) | 2001-09-05 | 2001-09-05 | Health-care products for regulating immunological function and delaying senility |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1336235A true CN1336235A (en) | 2002-02-20 |
| CN1121237C CN1121237C (en) | 2003-09-17 |
Family
ID=4670483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN01131281A Expired - Fee Related CN1121237C (en) | 2001-09-05 | 2001-09-05 | Health-care products for regulating immunological function and delaying senility |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN1121237C (en) |
| WO (1) | WO2003026683A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100353828C (en) * | 2004-06-04 | 2007-12-12 | 毛福森 | Composite fungus product for raising human body immunity and its prepn process |
| CN107441126A (en) * | 2017-08-01 | 2017-12-08 | 李庆杰 | It is a kind of that there is macro fungi composition for improving NK cell tumour killing activities and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085433A (en) * | 1993-07-03 | 1994-04-20 | 沈阳市好猫生物技术研究所 | Caoling nutrient solution and preparation method thereof |
| CN1083365A (en) * | 1993-08-11 | 1994-03-09 | 沈阳市好猫生物技术研究所 | North aweto nourishing wine and preparation method thereof |
| CN1051229C (en) * | 1994-11-30 | 2000-04-12 | 南京金宁信息技术研究所 | Preparation method of active dried earthworm powder |
| CN1170578A (en) * | 1996-07-17 | 1998-01-21 | 中国人民解放军第四军医大学 | Earthworm capsule |
-
2001
- 2001-09-05 CN CN01131281A patent/CN1121237C/en not_active Expired - Fee Related
-
2002
- 2002-09-04 WO PCT/CN2002/000616 patent/WO2003026683A1/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100353828C (en) * | 2004-06-04 | 2007-12-12 | 毛福森 | Composite fungus product for raising human body immunity and its prepn process |
| CN107441126A (en) * | 2017-08-01 | 2017-12-08 | 李庆杰 | It is a kind of that there is macro fungi composition for improving NK cell tumour killing activities and preparation method thereof |
| CN107441126B (en) * | 2017-08-01 | 2021-09-10 | 李庆杰 | Macro-fungus composition capable of improving NK cell tumor killing activity and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003026683A1 (en) | 2003-04-03 |
| CN1121237C (en) | 2003-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101624570B (en) | Method for cultivating cultured ganoderma lucidum with Chinese medicaments and method for preparing cultured ganoderma lucidum health-care product | |
| CN1762236A (en) | Health-caring product capable of increasing human immunity and its preparation method | |
| CN101805763B (en) | Inonotus obliquus extracellular and intracellular mixing crude polysaccharide with function of strengthening immunity | |
| CN1240390C (en) | Biologic converted ginseng composition and preparing process thereof | |
| CN101380346B (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| CN101716256B (en) | Preparation used for strengthening immunity | |
| CN101249259A (en) | High content and high activity oral polysaccharide-peptide and preparing method and application of the same | |
| CN1225209C (en) | Health food for cancer patient and preparing method thereof | |
| CN1136931A (en) | Ant ginseng oral liquid and preparing process thereof | |
| CN1121237C (en) | Health-care products for regulating immunological function and delaying senility | |
| CN105999096A (en) | Composition for enhancing immunity and application | |
| CN1686404A (en) | Dangshen astragalus composition for regulating immunity and its preparation method | |
| CN1218745C (en) | Health food for protecting liver and adjusting blood fat and method for preparing the same | |
| CN1903213A (en) | Traditional Chinese medicine preparation with functions of immunological regulation for anti-chemical damage | |
| CN1053376C (en) | Antineoplastic Chinese medicine prepn and its prepn process | |
| CN1793165A (en) | Process for producing asparagus saponin | |
| TW200920387A (en) | Composition of mushroom beta-glucan for anti-cancer and preparation method thereof | |
| CN109893603A (en) | It is a kind of to improve the composition of men's health, preparation method and applications | |
| CN1480207A (en) | Spore of gandoderma lucidum for treating disease of autoimmunity | |
| CN1421238A (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN1101559A (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN102133305A (en) | Composite of health-care matters or medicines used for improving immunity and preventing 'three high' and application thereof | |
| CN1919258A (en) | Application of schisandra chinensis in the preparation of medicine for preventing and reducing toxic and side effect of antitumor agent | |
| CN1772268A (en) | Medicine composition for raising immunity and its prepn and application | |
| CN1237984C (en) | Prepn. method of freezing-drying powder injection for anticancer made of Chinese herb medicines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1045105 Country of ref document: HK |